Interpretation of the skin cancer quality of life score: a validated quality of life questionnaire for non-melanoma skin cancer.

BACKGROUND: Health-related quality of life (HRQoL) instruments are used increasingly. In order to assign clinical meaning to HRQoL scores, the interpretation of instruments is essential but lagging in dermatology. OBJECTIVE: To establish a clinical interpretation of the Skin Cancer Quality of Life questionnaire (SCQoL), a newly validated HRQoL instrument for patients with non-melanoma skin cancer (NMSC), using an anchor-based method, and to test the responsiveness. METHODS: Receiver-operating characteristic analysis was used to propose clinically meaningful cut-off scores for SCQoL including 101 patients with NMSC. RESULTS: The following bands were established: score 0-3 corresponds to no impairment, 4-6 corresponds to mild impairment, 7-10 to moderate impairment and 11-27 to severe impairment of HRQoL. Testing the responsiveness shows a moderate effect size and significantly lower scores only for the domain emotion and the global item. CONCLUSION: Using proposed clinical cut-off scores for SCQoL may help clinicians in their decision-making, help monitoring clinical improvement and classify patients just as e.g. the Dermatology Life Quality Index can.

In-transit sentinel nodes must be found: implication from a 10-year follow-up study in melanoma.

The aim was to study the occurrence of in-transit nodes at a preoperative lymphoscintigraphy for patients with primary melanoma, and to reveal their potential role in prognosis. From 1984 to 1996, 911 patients, hospitalized for wide excision of a clinically localized primary cutaneous head-neck or truncal melanoma, had a static lymphoscintigraphy on the day before surgery as part of a prospective protocol. Lymph nodes were in no case removed at the time of scintigraphy. Recurrence and survival patterns were compared for patients with in-transit nodes with the remaining patients with only regional nodes. Follow-up time was a minimum of 10 years. In-transit nodes were visualized by lymphoscintigraphy in 6% of the patients, 18% of whom had a later recurrence in this region. The melanomas in the in-transit node group were slightly thicker, and ulceration was slightly more frequent (neither significant). The in-transit node group had significantly more lymph node basins visualized at scintigraphy compared with the remaining group of patients with only regional nodes. The risk of recurrence and/or death from melanoma was significantly worse (P<0.05) in the in-transit node group compared with the remaining patients. The clinical significance of the in-transit nodes, occasionally seen in melanoma patients (also in stage Ia), may suggest a slightly poorer prognosis and a substantial risk of a later recurrence in the in transit region. We therefore recommend that in-transit nodes must be found and examined exactly as is done with locoregional sentinel nodes.